Technology | Prostate Cancer | November 10, 2016

Augmenix Announces New Category 1 CPT Code for Periprostatic Implantation of Biodegradable Material

New AMA code establishes a standard reimbursement pathway for this new procedure performed with SpaceOAR technology

Augmenix, SpaceOAR System, prostate cancer, new CPT code, AMA, American Medical Association

November 10, 2016 — Augmenix Inc. announced that the American Medical Association (AMA) has granted a Category I, Current Procedural Terminology (CPT) code specifically for periprostatic implantation of biodegradable material. AMA granted the code with the support of the American Society for Radiation Oncology (ASTRO) and the American Urological Association (AUA).

The purpose of CPT is to provide a uniform language that accurately describes medical, surgical and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians and other healthcare providers, patients and third parties. The new CPT code is expected to become effective on Jan. 1, 2018 at which time the Category III code, 0438T, will be eliminated.

Following the recent presentation of positive three-year data from the SpaceOAR Pivotal Clinical Trial at the 2016 ASTRO Annual Meeting in Boston, AMA granted a Category 1 CPT code for periprostatic implantation of biodegradable material.

“SpaceOAR is clearly the most elegant and clinically proven technology for reducing rectal toxicity in the treatment of prostate cancer developed in the past 20 years,” said Steven Kurtzman, M.D., president, Western Radiation Oncology Inc., San Mateo, Calif. “I consider the product an integral part of my treatment protocol for patients receiving both external beam radiation therapy and brachytherapy.”

The leading side effects of prostate cancer radiotherapy are collectively known as “rectal toxicity” (diarrhea, rectal bleeding, urgency, pain, etc.), which results from unintended radiation injury to the rectum (the Organ At Risk, OAR). These complications can last for years, significantly impacting patient quality of life (QOL).

Using a minimally invasive procedure, Augmenix’s SpaceOAR System is injected as a liquid into the space between the prostate and rectum where it expands the space and then solidifies into a soft hydrogel. The hydrogel remains stable for three months while protecting the rectum during radiotherapy, and then liquefies and is completely absorbed by the body after radiotherapy is complete.

The SpaceOAR System is U.S. Food and Drug Administration (FDA)-cleared. It is also CE marked, approved in Australia and licensed in Canada.

For more information: www.augmenix.com

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Exact Imaging Partners to Improve Prostate Cancer Detection With Artificial Intelligence
News | Prostate Cancer | September 19, 2018
Exact Imaging, makers of the ExactVu micro-ultrasound platform, has partnered with U.K.-based Cambridge Consultants to...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
Feature | Radiology Business | September 07, 2018 | By Marilyn M. Singleton, M.D., J.D.
“Disruptive innovation” is all the buzz. Repealing the Affordable Care Act (ACA) is so last year. Well, disrupt this:...

Image courtesy of IBA

Feature | Radiation Oncology | September 07, 2018 | By Jeff Zagoudis
According to the latest statistics from the American Cancer Society (ACS), almost 165,000 new cases of prostate cancer...
GlobalData: Amazon Poised to Make Huge Strides in Healthcare
News | Radiology Business | August 31, 2018
A new report from data and analytics company GlobalData suggests that Amazon is poised to make huge strides in...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...